- $41.40bn
- $53.80bn
- $14.98bn
- 87
- 31
- 83
- 74
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 19.76 | ||
| PEG Ratio (f) | 0.82 | ||
| EPS Growth (f) | 31.73% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.77 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 27.6 | ||
| Price to Sales | 2.76 | ||
| EV to EBITDA | 17.38 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.76% | ||
| Return on Equity | 22.87% | ||
| Operating Margin | 13.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 11,088 | 11,359 | 13,874 | 14,410 | 14,984 | 15,529.19 | 16,656.49 | 7.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -2 | +31.82 | +203.32 | +13.33 | +32.45 | +43.57 | +12.84 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. The Company's Connected Intelligence delivers insights enabling customers to accelerate the clinical development and commercialization of medical treatments that improve healthcare outcomes for patients. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides mission critical information, technology solutions and real-world insights and services to life science clients. Research & Development Solutions primarily serves biopharmaceutical clients, provides outsourced clinical research and clinical trial services. Contract Sales & Medical Solutions provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical clients and the broader healthcare market.
Directors
- Ari Bousbib CHM (59)
- Ronald Bruehlman CFO (60)
- Kevin Knightly CEX (60)
- Walter Staub CEX (58)
- Eric Sherbet EVP (56)
- John Leonard LED (63)
- Carol Burt IND (63)
- John Connaughton IND (55)
- John Danhakl IND (65)
- James Fasano IND (51)
- Colleen Goggins IND (66)
- Ronald Rittenmeyer IND (73)
- Todd Sisitsky IND (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 3rd, 2016
- Public Since
- May 9th, 2013
- No. of Shareholders
- 15
- No. of Employees
- 87,000
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 181,500,000
- Address
- 2400 ELLIS ROAD, DURHAM, 27703
- Web
- https://ir.iqvia.com/
- Phone
- +1 9199982000
- Contact
- Nick Childs
- Auditors
- PricewaterhouseCoopers LLP
Latest News for IQV
Upcoming Events for IQV
Q1 2024 IQVIA Holdings Inc Earnings Release
Q1 2024 IQVIA Holdings Inc Earnings Call
Q2 2024 IQVIA Holdings Inc Earnings Release
Similar to IQV
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Biohaven
New York Stock Exchange
FAQ
As of Today at 19:11 UTC, shares in Iqvia Holdings are trading at $228.09. This share price information is delayed by 15 minutes.
Shares in Iqvia Holdings last closed at $228.09 and the price had moved by +14.85% over the past 365 days. In terms of relative price strength the Iqvia Holdings share price has underperformed the S&P500 Index by -4.42% over the past year.
The overall consensus recommendation for Iqvia Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Iqvia Holdings does not currently pay a dividend.
Iqvia Holdings does not currently pay a dividend.
Iqvia Holdings does not currently pay a dividend.
To buy shares in Iqvia Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $228.09, shares in Iqvia Holdings had a market capitalisation of $41.40bn.
Here are the trading details for Iqvia Holdings:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: IQV
Based on an overall assessment of its quality, value and momentum Iqvia Holdings is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Iqvia Holdings is $275.82. That is 20.93% above the last closing price of $228.09.
Analysts covering Iqvia Holdings currently have a consensus Earnings Per Share (EPS) forecast of $11.11 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Iqvia Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +5.03%.
As of the last closing price of $228.09, shares in Iqvia Holdings were trading +3.74% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Iqvia Holdings PE ratio based on its reported earnings over the past 12 months is 19.76. The shares last closed at $228.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Iqvia Holdings' management team is headed by:
- Ari Bousbib - CHM
- Ronald Bruehlman - CFO
- Kevin Knightly - CEX
- Walter Staub - CEX
- Eric Sherbet - EVP
- John Leonard - LED
- Carol Burt - IND
- John Connaughton - IND
- John Danhakl - IND
- James Fasano - IND
- Colleen Goggins - IND
- Ronald Rittenmeyer - IND
- Todd Sisitsky - IND